Boardroom Alpha
Boardroom Alpha
ANAB · Current Report (Form 8-K) · Filed June 22, 2026

Anaptysbio Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 22, 2026
Period
Jun 15, 2026
Ticker
ANAB
Accession
0001193125-26-277505
Boardroom Alpha · Filing insights

AnaptysBio subleases approximately 45,057 rentable square feet to First Tracks for 12 months, with renewal and termination rights.

About Anaptysbio Inc
Market cap
$1.6B
1Y TSR
+266.8%
3Y TSR
+62.3%
Board grade
B
Sector
Healthcare
CEO
Daniel Faga
Last annual meeting: Aug 11, 2026 · View full Anaptysbio Inc profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2026

 

 

ANAPTYSBIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37985

20-3828755

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10770 Wateridge Circle, Suite 210

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 362-6295

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.001 per share

 

ANAB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 1.01 Entry into a Material Definitive Agreement.

On June 15, 2026, AnaptysBio, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with First Tracks Biotherapeutics, Inc., a Delaware corporation (“First Tracks”), pursuant to which the Company agreed to sublease to First Tracks approximately 45,057 rentable square feet of space located at 10770 Wateridge Circle, San Diego, California 92121 (the “Premises”). The Premises are currently leased by the Company from Wateridge Property Owner, LP, a Delaware limited partnership (the “Master Landlord”), pursuant to the Lease dated May 4, 2020, as amended by the First Amendment to Lease Agreement dated April 5, 2021 (collectively, the “Master Lease”).

The term of the Sublease commenced on June 15, 2026, and continues for a period of twelve (12) months from commencement (the “Sublease Term”). First Tracks has the option to extend the Sublease Term for a renewal period commencing on the first day following the expiration of the initial Sublease Term and continuing until the earlier of (a) April 4, 2028, or (b) twelve months from the commencement of the renewal term, subject to delivery of written notice to the Company at least three months prior to the expiration of the initial Sublease Term. First Tracks also has the right to terminate the Sublease at any time during the Sublease Term upon at least three months’ prior written notice to the Company.

Under the Sublease, First Tracks is obligated to pay as monthly rent an amount equal to the monthly Basic Rent (as designated in the Master Lease) owed by the Company under the Master Lease, plus Additional Rent (as defined in the Master Lease) due under the Master Lease, payable in advance on the first day of each month during the Sublease Term. First Tracks is also responsible for any charges actually incurred for services requested by First Tracks that the Company is liable to the Master Landlord for under the Master Lease. The Company remains responsible for the timely payment of Basic Rent and Additional Rent under the Master Lease and for otherwise complying with its obligations under the Master Lease except to the extent assumed by First Tracks.

The Sublease is subordinate to the Master Lease, and First Tracks has agreed to comply with the applicable terms and provisions of the Master Lease as incorporated into the Sublease.

The Company has covenanted that it will not surrender or terminate the Master Lease prior to its scheduled expiration date without the consent of First Tracks (other than in connection with the exercise of its Termination Option (as defined in the Master Lease)), and will not amend or modify the Master Lease in any manner that would materially and adversely affect First Tracks’ rights or obligations under the Sublease. If the Company’s tenancy or right to possession under the Master Lease terminates for any reason, the Sublease will immediately cease and terminate.

The foregoing description of the Sublease does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Sublease, a copy of which will be filed with the Company’s transition report on Form 10-K/T for the transition period from January 1, 2026 to June 30, 2026.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ANAPTYSBIO, INC.

 

 

 

 

Date:

June 22, 2026

By:

/s/ Christopher M. Murphy

 

 

 

Name: Christopher M. Murphy
Title: Chief Financial Officer

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Anaptysbio Inc (ANAB)

Reference

Frequently asked questions

When did Anaptysbio Inc file this 8-K?
Anaptysbio Inc (ANAB) filed this Current Report (Form 8-K) with the SEC on June 22, 2026. The accession number assigned by EDGAR is 0001193125-26-277505.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
AnaptysBio subleases approximately 45,057 rentable square feet to First Tracks for 12 months, with renewal and termination rights. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Anaptysbio Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Anaptysbio Inc has filed under CIK 1370053, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer